BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 3, 2025
Discovery & Translation

Science Spotlight: Increasing penetration of CAR T cells into solid tumors

BioCentury’s roundup of translational innovations also includes an approach to induce TLSs, an underappreciated role for NK cells and newcos in literature
BioCentury | Oct 28, 2020
Distillery Therapeutics

Small molecule ERG, FLI1 inhibitor identified for retinopathy of prematurity

DISEASE CATEGORY: Ophthalmic
INDICATION: Retinopathy of prematurity A tool compound that inhibits multiple E26 transformation-specific transcription factors, including ERG and FLI1, could treat
BioCentury | Jun 23, 2020
Distillery Therapeutics

Repurposing antimalarial drug lumefantrine for glioblastoma

BioCentury | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH abstracts reveal new mechanisms and consequences of immune cell repolarization in hematology
BioCentury | Sep 19, 2018
Distillery Techniques

Drug platforms

BioCentury | Oct 24, 2016
Emerging Company Profile

RORing against resistance

Why Oncternal’s ROR1 inhibitor could pair with BTK in chemo-resistant cancers
BioCentury | Sep 5, 2016
Clinical News

TK216: Phase I started

BioCentury | Jun 6, 2016
Company News

Oncternal, Tokalas deal

BioCentury | Jul 24, 2014
Distillery Techniques

Technology: Disease models

BioCentury | Jan 27, 2014
Emerging Company Profile

Salarius: Kicking LSD

Salarius developing inhibitors for LSD1-dependent cancers, like AML, Ewing's
Items per page:
1 - 10 of 15